Could buying these ASX shares at $9 now be like investing in Tesla in 2010?

This Melbourne company is making big strides in its field and has returned a phenomenal 67% each year for its investors already.

| More on:
A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I discussed earlier this month how it took a while for Tesla Inc (NASDAQ: TSLA) to become a brand name synonymous with the entire electric vehicle industry.

Those investors courageous enough to buy split-adjusted US$1.13 shares at the initial public offering (IPO) in 2010 have now been handsomely rewarded.

A $10,000 purchase of Tesla stocks back then would now be worth an amazing $2.13 million.

The point of bringing up that journey is not to annoy you that you missed out on the sweet action. Rather it serves to highlight how backing outstanding businesses early on and persisting for the long term can produce incredible riches.

While no one knows what will happen in the future, there are ASX shares with the potential to execute Tesla-esque growth in the years to come.

Let's break down one such candidate:

Revenue up 9x, share price up 13x

Telix Pharmaceuticals Ltd (ASX: TLX) makes diagnostic and treatment products for cancer.

The last 18 months have been a whirlwind for the Melbourne business.

Its prostate cancer imaging agent Illuccix went commercial last year, while products for other forms of cancer are undergoing trials or approval stages.

Revenue was, incredibly, up nine-fold in the 2023 financial year compared to the year before. And despite having so many products still progressing through the pre-commercial stages, Telix was cash flow positive.

Therefore it may not surprise you that the Telix share price has already multiplied 13 times over the past five years.

That's a crazy compound annual growth rate (CAGR) of 67%.

How's the outlook for these ASX shares?

Despite the explosive growth already behind it, there are plenty of reasons to suggest Telix could keep going over the next few years.

The first is all that revenue growth came from just one product, Illuccix. The company has many others in development, to deal with cancers in different parts of the body.

Of course, there is no guarantee they will all make it out the other side of medical trials and regulatory approvals. But even if some of them can join Illuccix as a paying product in the coming years, Telix's investors will be very happy.

The other ace up Telix's sleeve is that it has the balance sheet to make acquisitions.

In fact, it has already started playing this card. 

Just this week the business announced the acquisition of US outfit Qsam Biosciences, which is developing therapies for various types of cancer. At the start of this month, Telix completed the takeover of surgery technology provider Lightpoint Medical.

Many professional investors are believers in Telix.

According to CMC Markets, all seven analysts that cover the stock currently rate it as a buy.

Motley Fool contributor Tony Yoo has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals and Tesla. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A young man goes over his finances and investment portfolio at home.
Growth Shares

1 ASX growth stock down 30% to buy right now

The market has reacted badly to this ASX 200 company's half-year result. This could be your chance to get in.

Read more »

A man in his 30s with a clipped beard sits at his laptop on a desk with one finger to the side of his face and his chin resting on his thumb as he looks concerned while staring at his computer screen.
Growth Shares

This ASX growth stock is down 25%: Buy, sell, or hold?

Analysts have given their verdict on this beaten down growth share.

Read more »

A woman shows her phone screen and points up.
Growth Shares

2 ASX shares showing 'strong growth' that offer value right now

This pair of quality stocks have upward momentum that can't be denied right now, rising 38% and 15% since the…

Read more »

A young boy sits on his father's shoulders as they flex their muscles at sunrise on a beach
Growth Shares

I'd buy these great ASX growth shares in March

Growth stocks could achieve strong returns.

Read more »

A woman smiles as she sits on the bus using her phone and listening to music through headphones.
Growth Shares

1 ASX stock I think is just as hot as Nvidia (without all the hype)

There is an Australian business going as well as the US chip maker. Check this out.

Read more »

Happy man working on his laptop.
Growth Shares

1 ASX growth stock down 40% to buy right now

Goldman Sachs thinks this beaten down stock could be great value.

Read more »

A woman holds a tape measure against a wall painted with the word BIG, indicating a surge in gowth shares
Growth Shares

Goldman Sachs says these ASX growth shares are destined for big things

There's a reason Goldman has slapped buy ratings on these shares.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Growth Shares

A hot ASX stock with 'multiple catalysts' looming is 8% down. Time to buy

The Blackwattle team is still bullish on these pharmaceutical shares despite a recent sell-off.

Read more »